Clinical Trial Update: Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating docetaxel and erlotinib in advanced non-small cell lung cancer and other solid tumors has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Unspecified Adult Solid Tumor

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: University of California, Davis | Conditions: Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-10-26